
|Articles|February 15, 2007
Orphan status given to two drugs
Jersey City, NJ-The FDA has granted orphan drug designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing in treatments for ophthalmic diseases.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dr. Mali’s top 5 predictions in ophthalmology for 2026
2
FDA clears Novaliq’s Investigational New Drug application for NOV05
3
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
4
Eye exams could enable earlier detection of systemic disease
5



























